FMR LLC cut its position in Novo Nordisk A/S (NYSE:NVO) by 2.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,307,625 shares of the company’s stock after selling 51,706 shares during the period. FMR LLC owned about 0.09% of Novo Nordisk A/S worth $120,712,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $540,000. Comerica Securities Inc. lifted its position in Novo Nordisk A/S by 12.0% during the 4th quarter. Comerica Securities Inc. now owns 11,443 shares of the company’s stock worth $527,000 after acquiring an additional 1,223 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in Novo Nordisk A/S by 273.3% during the 4th quarter. Canada Pension Plan Investment Board now owns 165,000 shares of the company’s stock worth $7,601,000 after acquiring an additional 120,800 shares during the last quarter. FDx Advisors Inc. lifted its position in Novo Nordisk A/S by 70.7% during the 4th quarter. FDx Advisors Inc. now owns 10,247 shares of the company’s stock worth $472,000 after acquiring an additional 4,244 shares during the last quarter. Finally, Toronto Dominion Bank lifted its position in Novo Nordisk A/S by 117.1% during the 4th quarter. Toronto Dominion Bank now owns 64,131 shares of the company’s stock worth $2,957,000 after acquiring an additional 34,590 shares during the last quarter. 7.13% of the stock is owned by institutional investors.
Shares of NVO stock traded down $0.03 during trading hours on Thursday, hitting $48.28. 1,522,611 shares of the company were exchanged, compared to its average volume of 1,400,112. The stock has a market cap of $118.13 billion, a P/E ratio of 19.16, a PEG ratio of 2.19 and a beta of 0.60. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $52.83. The company has a 50 day moving average of $50.03. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07.
NVO has been the subject of a number of research analyst reports. Deutsche Bank reaffirmed a “buy” rating and set a GBX 2,450 ($32.01) price objective on shares of in a research report on Thursday, June 20th. UBS Group cut shares of to a “neutral” rating and lowered their target price for the company from GBX 870 ($11.37) to GBX 650 ($8.49) in a research note on Wednesday, June 19th. Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Credit Suisse Group reaffirmed a “sell” rating and set a $6.50 price objective on shares of Deutsche Bank in a research note on Monday, April 29th. Finally, Zacks Investment Research cut shares of General Finance from a “buy” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $111.58.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Recommended Story: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.